Publicité
English Flag
Biotech Finances - L'information stratégique des biodécideurs et des bioinvestisseurs
RECHERCHER SUR LE SITE
ET DANS LES ARCHIVES
dimanche 21 dcembre 2014
 Mmoriser  
 
 

Communiqu de Presse

Spectrum Pharmaceuticals to Present at the Citi 2012 Global Health Care and the RBC Capital Markets Health Care Conferences

Le 24/02/2012 13:02

Feb. 24, 2012 12:00 UTC

Spectrum Pharmaceuticals to Present at the Citi 2012 Global Health Care and the RBC Capital Markets Health Care Conferences

  • Corporate Overview to be Presented on Monday, February 27th and Wednesday, February 29th
Citi Global Health Care Conference 2012 RBC Capital Markets Healthcare Conference 2012

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that an overview of the Company's business strategy will be given at two investor conferences.

Monday, February 27 at 8:30am Eastern Time
Citi Global Health Care Conference at the Waldorf=Astoria Hotel in New York City

Wednesday, February 29 at 3:30pm Eastern Time
RBC Capital Markets Healthcare Conference at the Palace Hotel in New York City

The live webcast of Spectrum's corporate presentations will be available at http://www.sppirx.com.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, a biotechnology company with a primary focus in oncology and hematology, currently markets two oncology drugs, FUSILEV (levoleucovorin) for Injection and ZEVALIN(ibritumomab tiuxetan) Injection for intravenous use. In addition, Spectrum has two drugs, apaziquone and belinostat, in late stage development with a goal of filing New Drug Applications (NDAs) with the U.S. Food & Drug Administration in 2012. The Company also has a diversified pipeline of novel drug candidates. The Company's strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial drug products. The Company has aggressive business development and commercial operation teams that support a robust drug development program encompassing clinical development, medical research, regulatory affairs, biostatistics and data management. The Company also leverages the expertise of its worldwide partners to assist in the execution of its strategy. For more information, please visit the Company's website at www.sppirx.com.

Forward-looking statement ? This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include but are not limited to statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees, around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new applications to the FDA may not receive approval, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC., ZEVALIN, and FUSILEV are registered trademarks of Spectrum Pharmaceuticals, Inc. REDEFINING CANCER CARE? and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.

2012 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

Contacts

Spectrum Pharmaceuticals, Inc.
Shiv Kapoor
Vice President, Strategic Planning & Investor Relations
702-835-6300
or
Paul Arndt
Senior Manager, Investor Relations
702-835-6300


Source: Spectrum Pharmaceuticals, Inc.